USD
$0.00
(0.00%
)At Close (As of Dec 17, 2025)
$172.20M
Market Cap
-
P/E Ratio
-1.92
EPS
$5.14
52 Week High
$0.75
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $486K |
| Total Revenue | $486K |
| Cost Of Revenue | $635K |
| Costof Goods And Services Sold | $635K |
| Operating Income | -$56M |
| Selling General And Administrative | $17M |
| Research And Development | $39M |
| Operating Expenses | $56M |
| Investment Income Net | - |
| Net Interest Income | $4.6M |
| Interest Income | $4.6M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $635K |
| Income Before Tax | -$51M |
| Income Tax Expense | $7K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$51M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$56M |
| Ebitda | -$55M |
| Net Income | -$51M |
| Field | Value (USD) |
|---|---|
| Total Assets | $84M |
| Total Current Assets | $82M |
| Cash And Cash Equivalents At Carrying Value | $67M |
| Cash And Short Term Investments | $67M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $2.3M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $13M |
| Other Current Assets | $1.6M |
| Other Non Current Assets | - |
| Total Liabilities | $14M |
| Total Current Liabilities | $13M |
| Current Accounts Payable | $653K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $561K |
| Total Non Current Liabilities | $1.3M |
| Capital Lease Obligations | $1.5M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $1.5M |
| Other Current Liabilities | $8.8M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $70M |
| Treasury Stock | - |
| Retained Earnings | -$408M |
| Common Stock | $29K |
| Common Stock Shares Outstanding | $31M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $486K |
| Total Revenue | $486K |
| Cost Of Revenue | $635K |
| Costof Goods And Services Sold | $635K |
| Operating Income | -$56M |
| Selling General And Administrative | $17M |
| Research And Development | $39M |
| Operating Expenses | $56M |
| Investment Income Net | - |
| Net Interest Income | $4.6M |
| Interest Income | $4.6M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $635K |
| Income Before Tax | -$51M |
| Income Tax Expense | $7K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$51M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$56M |
| Ebitda | -$55M |
| Net Income | -$51M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
VistaGen Therapeutics Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to developing innovative therapeutics for anxiety, depression, and other central nervous system disorders. The company’s lead product candidate, AV-101, is designed to fulfill significant unmet needs within the mental health treatment landscape, underscoring its commitment to advancing effective neuropharmacological solutions. With a promising pipeline of therapies and a strategic focus on addressing the evolving demands of CNS therapeutics, VistaGen offers a compelling investment opportunity for institutional investors looking to engage with groundbreaking advancements in healthcare.